These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 14723002)

  • 1. State-of-the-art treatment for advanced non-small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 13):15-22. PubMed ID: 14723002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of unresectable non-small cell lung cancer.
    Livingston RB
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):4-11; discussion 11-3. PubMed ID: 7973768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies.
    Gordon GS; Vokes EE
    Oncology (Williston Park); 1999 Aug; 13(8):1075-88; discussion 1088, 1091-4. PubMed ID: 10499243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
    Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
    J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy in metastatic and locally advanced non-small cell lung cancer.
    Spigel DR; Greco FA
    Semin Surg Oncol; 2003; 21(2):98-110. PubMed ID: 14508860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
    Belani CP
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):44-54. PubMed ID: 10190783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer].
    Bunn PA
    Anticancer Drugs; 2001 Jul; 12 Suppl 3():S3-8. PubMed ID: 11556251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet chemotherapy combinations with new agents: is there a rationale?
    Bunn PA
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):55-61. PubMed ID: 9728586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future beyond platinum for the treatment of advanced non-small cell lung cancer.
    Dragnev KH; Rigas JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):73-6. PubMed ID: 10585012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
    Langer CJ
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):19-24. PubMed ID: 11221017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.